ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621

Its studies are mostly in Prostatic Neoplasms, led by AstraZeneca.

Furthest: phase 2, since Jul 11, 20251 company-led study, 1 open or runningNext primary completion: Mar 29, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 2since Jul 11, 2025Jul 11, 2025Mar 29, 2029phase 2 · NCT07192614
  • Named in AstraZeneca’s own pipeline as AZD6621, phase 1, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 11, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT07192614 · 52 planned · United States, Belgium, Canada and more

Ahead

  1. Mar 29, 2029Primary completion: phase 2 study in Prostatic NeoplasmsNCT07192614

TargetBeta

“A trispecific T-cell engager and antibody targeting the tumor-associated antigen (TAA) metalloreductase six-transmembrane epithelial antigen of prostate-2 (STEAP2; STAMP1), and the T-cell surface antigens CD3 and CD8, with potential immunostimulating and antineoplastic activities. Upon administra…”NCIt, read by Claude
“A trispecific T-cell engager and antibody targeting the tumor-associated antigen (TAA) metalloreductase six-transmembrane epithelial antigen of prostate-2 (STEAP2; STAMP1), and the T-cell surface antigens CD3 and CD8, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07192614Prostatic Neoplasms · United States, Belgium, Canada and more2RecruitingMar 29, 202952

How it is read

Names in the registry

  • “AZD6621”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.